Menu
Back to Journals » Biologics: Targets and Therapy » Volume 2 » Issue 1
Review
The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease - An interview with David A Schwartz, 13 June 2007
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 7,588 | Dovepress* | 7,588+ | 1,590 | 9,178 | |
| Totals | 7,588 | 1,590 | 9,178 | ||
|
*Since 7 March 2008 +Since July 2016 |
|||||
View citations on Google Scholar